Favipiravir Suppliers & Bulk Manufacturers
Available Forms: Tablets
Available Strengths: 200 mg
Reference Brands:
Category:
Anti Covid Medicines
Favipiravir 200 mg is the first oral antiviral medication under the trade name FabiFlu for the treatment of mild to severe COVID-19 cases, Glenmark Pharmaceutical launch this medication. This medicine shows 80-88% efficacy in global clinical trials and it is currently used in Japan and UAE for the Covid-19 treatment.
Favipiravir is available in Tablets
and strengths such as 200 mg.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Favipiravir is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Favipiravir can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Favipiravir should be taken orally at about the same time each day, either with or without food. Favipiravir tablets should be swallowed whole with water. The tablet should not be opened, broken, or chewed. For patients with COVID-19, the usual dosage of favipiravir for adults is 1800 mg orally twice daily on day 1, followed by 800 mg orally twice daily for 14 days.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing